Business Overview: Biotricity Inc. (BTCY)

Executive Summary

Biotricity Inc. is a Technology-as-a-Service (TaaS) company providing remote, clinical-grade cardiac monitoring solutions that allow healthcare providers to monitor patients for cardiovascular conditions outside traditional clinical settings. The company's Cardiac AI Cloud platform, trained on over two trillion anonymized heartbeats, underpins both provider-facing diagnostic devices and consumer-facing products such as Bioheart. In its third quarter of fiscal 2026, Biotricity reported revenue of $4.0 million (up 10.2% year-over-year), with recurring technology fees representing 91.2% of revenue and gross margin improving to 81.5%. Notably, the company posted its third consecutive quarter of positive EBITDA while narrowing its net loss to $1.1 million, suggesting a maturing, increasingly self-sustaining business model after years of investment in its monitoring platform.

Core Business Model

Biotricity operates on a recurring-revenue, technology-enabled service model: rather than simply selling monitoring hardware, it charges recurring technology fees for continuous access to its remote cardiac monitoring and diagnostic platform, which combines wearable/implantable sensor devices with a cloud-based AI diagnostic engine. This SaaS-like recurring fee structure (91.2% of Q3 FY26 revenue) provides more predictable, higher-margin revenue than a one-time device-sale model, and the company is actively pursuing FDA clearance for its AI clinical model to further differentiate its diagnostic capabilities.

Product Portfolio

• Cardiac AI Cloud platform — the core diagnostic engine, trained on a massive anonymized heartbeat dataset, supporting automated and clinician-assisted diagnostic workflows.
• Bioheart — a consumer-focused continuous cardiac monitoring device.
• Remote cardiac monitoring devices — clinical-grade wearable monitoring hardware used by the company's network of over 2,500 healthcare providers serving approximately 4 million patients annually.

Competitive Landscape

Biotricity competes in the remote cardiac monitoring (RCM) and remote patient monitoring (RPM) market against established medical device and diagnostics companies (such as iRhythm Technologies, BioTelemetry/Philips, and various hospital-affiliated telehealth cardiac monitoring providers), as well as emerging digital health startups targeting chronic cardiovascular disease management. Biotricity's differentiation centers on its AI-driven diagnostic platform and its recurring-fee, technology-enabled service model rather than a hardware-sale approach, along with an expanding international regulatory footprint (Canada, Saudi Arabia, Argentina) that could support future distribution partnerships.

Strategic Strengths & Risks

Strengths

• High recurring-revenue mix (91.2% of revenue from recurring technology fees) provides revenue predictability uncommon among smaller medical device companies.
• Improving unit economics: gross margin expansion (76.4% to 81.5%) and three consecutive quarters of positive EBITDA signal a maturing, increasingly efficient business model.
• Large proprietary diagnostic dataset (two trillion+ anonymized heartbeats) could support ongoing AI model improvements that are difficult for smaller competitors to replicate.
• Established provider network (2,500+ healthcare providers, 4 million patients served annually) provides a real, scaled distribution base.
• International expansion optionality via recent regulatory approvals in Canada, Saudi Arabia, and Argentina.

Risks

• Continued net losses: despite improving EBITDA, the company still reported a net loss in the most recent quarter, meaning it has not yet achieved full GAAP profitability.
• Regulatory dependency: pending FDA clearance for its AI clinical model is a meaningful catalyst but also a risk if delayed or denied.
• Reimbursement risk: remote cardiac monitoring reimbursement policies (Medicare and private payers) can change, directly affecting revenue, similar to broader dynamics affecting reimbursement-dependent healthcare technology companies.
• Competitive intensity: larger, better-capitalized medical device and digital health companies could out-invest Biotricity in AI diagnostic capability and provider relationships.
• Small scale: at roughly $4 million in quarterly revenue, Biotricity remains a small player relative to larger remote cardiac monitoring competitors.

Financial Overview

Summary Conclusion

Biotricity has built a genuinely differentiated, AI-driven remote cardiac monitoring platform with an increasingly favorable recurring-revenue mix and improving profitability trajectory, evidenced by three consecutive quarters of positive EBITDA. Its large proprietary diagnostic dataset and established provider network provide real competitive assets, but the company remains small relative to larger, well-capitalized remote monitoring competitors and continues to operate at a net loss while pursuing further regulatory clearances. Its moat is emerging but not yet fully established — dependent on continued execution, successful AI/FDA clearance, and defense of its reimbursement position within a competitive digital health landscape.